Previous 10 | Next 10 |
Orchard Therapeutics ([[ORTX]] +3.4%) has expanded its multi-year partnership with Be The Match BioTherapies, ahead of its European commercial launch of Libmeldy (autologous CD34+ cells encoding the ARSA gene).With the amended agreement, Be The Match BioTherapies which previously helped in ce...
Be The Match BioTherapies will provide streamlined supply chain services in support of Orchard’s commercial-stage gene therapy in Europe Be The Match BioTherapies , an organization offering solutions for companies developing and commercializing cell and gene thera...
$150M Strategic Financing Supports Execution into the First Half of 2023 OTL-203 Achieves Proof of Concept (POC) in MPS-I Hurler Syndrome (MPS-IH); Registrational Trial Planned to Initiate by Year End 2021 OTL-200 U.S. Filing Strategy for Metachromatic Leukodystrophy (ML...
BOSTON and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following virtual investor conferences: Cowen 41 st Annual Healthcare Conference on Mar...
Before the open, bluebird bio ([[BLUE]] -33.6%) announced it was suspending two Phase 1/2 clinical trials for the gene therapy candidate, LentiGlobin in sickle cell disease (“SCD”)The investigations were ongoing to determine if there was a relationship to the use of BB305 lentiv...
bluebird bio (BLUE) -30% after suspending sickle cell disease trial.Hepion Pharmaceuticals (HEPA) -28% after pricing stock offering.Cortexyme (CRTX) -26% after regulatory update on Atuzaginstat in Alzheimer’s Disease.Neptune Wellness Solutions (NEPT) -21%&...
Orchard Therapeutics (ORTX) climbed ~14.3% yesterday after the company announced new data from its hematopoietic stem cell (“HSC”) gene therapies undergoing development for neurodegenerative disorders.The interim data included the clinical proof-of-concept results for OTL-203 fo...
Shares of gene-therapy specialist Orchard Therapeutics (NASDAQ: ORTX) were trading sharply higher on Tuesday after the company released updates on two of its candidate treatments. As of 2:30 p.m. EST, Orchard stock was up by 10.7%, after having been up by as much as 21.9% earlier in...
All eight patients treated with OTL-203 show stable cognitive function, motor function and growth within the normal range at multiple data points post-treatment Supportive initial OTL-201 biomarker data for mucopolysaccharidosis type IIIA (MPS-IIIA or Sanfilippo syndrome type A)...
Orchard Therapeutics (ORTX) trades 10.5% high in premarket trade after executing a securities purchase agreement to raise gross proceeds of $150M through the sale of 24.1M shares in a PIPE financing at $6.22/share.Proceeds to be used for supporting its growing commercial capabilitie...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....